Anaptysbio (ANAB) Income from Continuing Operations (2016 - 2026)
Anaptysbio's (ANAB) quarterly Income from Continuing Operations came in at 52884000.0 in Q1 2026, down 34.47% YoY from 80696625.9 in Q1 2025, and down 205.29% on a QoQ basis from 50227000.0 in Q4 2025.
Powered by 
Analysis
Anaptysbio (ANAB) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of Income from Continuing Operations data on file, last reported at 52884000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 34.47% year-over-year to 52884000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 26174000.0 (up 76.23% YoY) and the FY2025 annual result came in at 12619000.0, up 89.0% from the prior year.
- Income from Continuing Operations slipped to 52884000.0 in Q1 2026, from 50227000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 50227000.0 in Q4 2025 to a low of 62550000.0 in Q1 2023.
- A 5-year average of 31170470.59 and a median of 39329000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations plunged 94.94% — and 2025, when it soared 476.2%.
- Tracing ANAB's Income from Continuing Operations over 5 years: stood at 22718000.0 in 2022, then sank by 85.61% to 42168000.0 in 2023, then surged by 120.67% to 8717000.0 in 2024, then soared by 476.2% to 50227000.0 in 2025, then slumped by 205.29% to 52884000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 52884000.0 (Q1 2026), 50227000.0 (Q4 2025), and 15113000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Anaptysbio | 1.62 Bn | 1.34 Bn | - | -52.88 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -52.88 Mn |
| Dec 31, 2025 | 52.52 Mn |
| Sep 30, 2025 | 15.11 Mn |
| Jun 30, 2025 | -38.63 Mn |
| Mar 31, 2025 | -39.33 Mn |
| Dec 31, 2024 | 8.58 Mn |
| Sep 30, 2024 | -32.85 Mn |
| Jun 30, 2024 | -46.66 Mn |
| Mar 31, 2024 | -43.94 Mn |
| Dec 31, 2023 | -7.85 Mn |
| Sep 30, 2023 | -37.31 Mn |
| Jun 30, 2023 | -39.85 Mn |
| Mar 31, 2023 | -39.92 Mn |
| Dec 31, 2022 | -22.13 Mn |
| Sep 30, 2022 | -27.37 Mn |
| Jun 30, 2022 | -26.69 Mn |
| Mar 31, 2022 | -31.41 Mn |
| Dec 31, 2021 | -31.09 Mn |
| Sep 30, 2021 | -6.70 Mn |
| Jun 30, 2021 | -429,000.00 |